AARTIPHARM vs BIOCON: Stock Comparison
BIOCON is the larger company by market capitalisation. AARTI PHARMALABS shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AARTIPHARM leads 10; BIOCON leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AARTIPHARM | BIOCON |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AARTIPHARM | BIOCON |
|---|---|---|
| Live Price | ₹858.8 | ₹397.4 |
| Day Change | -1.07% | -1.14% |
| Volume | 4.63 L | 31.09 L |
| 52-Week High | ₹946.1 | ₹447.15 |
| 52-Week Low | ₹585 | ₹337.05 |
| Distance from 52W High | -9.23% | -11.13% |
Valuation
| Metric | AARTIPHARM | BIOCON |
|---|---|---|
| Market Cap | ₹7,812 Cr | ₹64,740 Cr |
| P/E Ratio | 36.83x | 119.79x |
| P/B Ratio | 3.71x | 1.91x |
| EPS | ₹8.4 | ₹0.87 |
| Book Value | ₹234.3 | ₹224.71 |
| Dividend Yield | 0.46% | 0.13% |
Growth
| Metric | AARTIPHARM | BIOCON |
|---|---|---|
| Revenue Growth (TTM YoY) | 3.3% | 2.3% |
| EPS Growth (TTM YoY) | -30.8% | -72.5% |
| Qtr Sales Growth | 0.23% | 594.32% |
| Qtr Profit Growth | 6.78% | 162.07% |
Profitability & Leverage
| Metric | AARTIPHARM | BIOCON |
|---|---|---|
| ROE | 9.48% | 1.01% |
| ROCE | 8.38% | 2.42% |
| Net Margin | 10.25% | 2.29% |
| Operating Margin | 16.52% | 8.5% |
| Debt to Equity | 0.35x | 0.4x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AARTIPHARM | BIOCON |
|---|---|---|
| Promoter Holding | 42.69%▼ 0.22 pp | 29.73%▼ 0.17 pp |
| FII Holding | 8.17%▼ 0.22 pp | 8.14%▲ 0.62 pp |
| DII Holding | 7.22%▼ 0.19 pp | 23.38%▼ 0.69 pp |
| Public Holding | 41.74%▲ 0.63 pp | 23.75%▲ 0.34 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI PHARMALABS and BIOCON.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.